New Clinical Trial Data in Advanced Melanoma Presented at ASCO 2018: How Will it Change How You Practice?

Sanjiv S. Agarwala, MD

Video Categories: 2018 ASCO Insights and Video Library

Dr Sanjiv Agarwala talks about exciting new results presented at ASCO 2018 in melanoma, including the durability of anti–PD-1 therapy in providing 40% overall survival at 5 years, updates on adjuvant therapy showing superiority of anti–PD-1 over anti–CTLA-4, and new results in combining immunotherapies.

October 16, 2015

Anti-CTLA4 vs. Anti-PD-1

Dr. Sanjiv Agarwala examines the benefits of anti-PD-1 therapy vs. anti-CTLA4 therapy and how these therapies may be used on their own and in combination with each other in the future.

January 30, 2014

The Value Equation and Personalized Medicine

Dr Argawala discusses how the cost, access and quality of oncology care will be defined with new personalized medicine strategies and therapies.